3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Phase 1
2
Phase 1/2
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
5
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Disease Progression
2
Triple Negative Breast Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Interventions
Prednisone
53
Radiotherapy
52
Docetaxel
51
Leuprolide
48
Goserelin
47
bicalutamide
45
enzalutamide
28
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
27
Androgen Antagonists
27
Flutamide
24
Triptorelin Pamoate
22
apalutamide
18
Gonadotropin-Releasing Hormone
18
Abiraterone Acetate
17
Radiation
15
abiraterone
14
Zoledronic Acid
14
Magnetic Resonance Spectroscopy
13
gallium 68 PSMA-11
12
Prednisolone
11
luprolide acetate gel depot
10
darolutamide
9
Radiosurgery
9
cabazitaxel
8
Standard of Care
8
Specimen Handling
8
Radiotherapy, Intensity-Modulated
8
Radiotherapy, Conformal
8
Estramustine
8
Dexamethasone
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Prostatic Neoplasms
×
capivasertib
×
Clear all
NCT04493853
2026-05-05
CAPItello-281
AstraZeneca
Phase 3
Active not recruiting
1,012 enrolled
NCT05348577
2025-01-27
CAPItello280
AstraZeneca
Phase 3
Active not recruiting
1,035 enrolled